Expression Manufacturing — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Expression Therapeutics is a private, U.S.-based biotech firm founded in 2009, specializing in RNA and gene therapy. Its core differentiation lies in its proprietary eCO AI platform for optimizing gene expression and its extensive, proven CDMO capabilities for manufacturing lentiviral vectors and cell therapy products. Led by industry veteran William Swaney, the company has a track record of manufacturing over 100 cGMP products, including contributions to FDA-approved therapies like CARVYKTI®, positioning it at the intersection of innovative platform technology and clinical-stage manufacturing services.

RNA & Gene Therapy

Technology Platform

Expression Cassette Optimization (eCO): An AI/ML-driven platform that optimizes nucleic acid sequences for enhanced, tissue-directed transgene expression in mRNA, AAV, and lentiviral therapies. LENTeT: A proprietary, optimized third-generation lentiviral vector production system designed for higher titer and improved safety.

Opportunities

The company is positioned to capture significant growth in the outsourced cell and gene therapy manufacturing market due to its proven CDMO track record and state-of-the-art facility.

Its proprietary eCO AI platform presents a major opportunity to differentiate both its service offerings and its internal therapeutic programs by potentially creating best-in-class vectors with enhanced efficacy and safety profiles.

Risk Factors

The company relies heavily on its key manufacturing leader and faces intense competition in the CDMO space from larger, more established players.

The commercial and clinical value of its core eCO technology platform remains unproven, carrying the risk that it may not deliver a significant advantage over existing gene optimization methods.

Competitive Landscape

In manufacturing, Expression competes with large, global CDMOs like Lonza, Catalent, and Thermo Fisher, as well as specialized gene therapy CMOs. Its eCO platform competes with other gene design and optimization tools from companies like Dyno Therapeutics, 64x Bio, and Code Biotherapeutics. Its integrated model of platform + manufacturing is a key differentiator.

More companies in Cell & Gene Therapy →More companies in United States →